Status:
RECRUITING
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Lead Sponsor:
Zagazig University
Conditions:
Warts
Human Papilloma Virus
Eligibility:
All Genders
9+ years
Phase:
PHASE2
Brief Summary
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
Detailed Description
* Group A: 54 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-we...
Eligibility Criteria
Inclusion
- patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
Exclusion
- Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Key Trial Info
Start Date :
April 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 6 2025
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT05291845
Start Date
April 3 2022
End Date
December 6 2025
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Reham Essam
Zagazig, Al Sharqia, Egypt, 2543